<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The objective of our study is to evaluate the clinical response, steroid-sparing and adverse affects of long-term intravenous immunoglobulin (IVIG) treatment for <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Patients were recruited from the Rheumatology clinic </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients fulfilled the ACR criteria for the appropriate <z:hpo ids='HP_0002960'>autoimmune disease</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Beneficial effects of IVIG therapy in <z:hpo ids='HP_0002725'>systemic lupus erythematosus</z:hpo> (SLE) patients were evaluated utilizing the SLEDAI score </plain></SENT>
<SENT sid="4" pm="."><plain>Clinical remission in patients with other <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo> was evaluated by a rheumatologist </plain></SENT>
<SENT sid="5" pm="."><plain>Data were retrieved retrospectively from an IVIG database (Excel program) </plain></SENT>
<SENT sid="6" pm="."><plain>Seventeen patients-SLE (n = 11) and other <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo> (n = 6)-received a high dose IVIG protocol monthly for 6 months, followed by therapy every 2-3 months </plain></SENT>
<SENT sid="7" pm="."><plain>The patients received a mean of 7.9 courses/patient </plain></SENT>
<SENT sid="8" pm="."><plain>The mean follow-up for long-term therapy was 30 months </plain></SENT>
<SENT sid="9" pm="."><plain>The response to IVIG treatment was remission in 12 patients </plain></SENT>
<SENT sid="10" pm="."><plain>Change in the SLEDAI score following IVIG therapy was significant (p &lt; 0.05) </plain></SENT>
<SENT sid="11" pm="."><plain>In responders, IVIG harbored a significant steroid-sparing effect (p &lt; 0.05) </plain></SENT>
<SENT sid="12" pm="."><plain>Mild and transient adverse effects persisted with long-term therapy in 50% of patients </plain></SENT>
<SENT sid="13" pm="."><plain>Severe adverse effects (<z:hpo ids='HP_0002204'>pulmonary embolism</z:hpo> and <z:hpo ids='HP_0001250'>seizures</z:hpo>) occurred early in two patients with SLE and secondary anti-<z:chebi fb="0" ids="16247">phospholipid</z:chebi> syndrome </plain></SENT>
<SENT sid="14" pm="."><plain>Long-term IVIG therapy is beneficial and carries a good safety profile for SLE and other <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo> </plain></SENT>
</text></document>